Tier 2 — strong

Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial

Chen S, Shen W, Liu Y, Dong Q, Shi Y
Chinese medical journal 2023 136(14):1690-1698

Bibliography

PubMed
PMID 37469024
PubMed Central
PMC10344537
DOI
10.1097/cm9.0000000000002696
Funding
Supported by the Shaanxi Key Research and Development program, project 2023-ZDLSF-35.
Competing interests
The publication contains author disclosures. Commercial relationships, employment, funding or other interests should be interpreted from the complete declaration; it is not classified here as conflict-free.

Study snapshot

DesignOpen-label three-arm randomized eradication trial
ModelHuman participants; see population
Sample300 randomized; 263 completed
InterventionBerberine 500 mg twice/day plus amoxicillin/vonoprazan versus two quadruple regimens
Duration14 days; post-treatment eradication test
EndpointsEradication or stool-output outcomes; Treatment tolerability; Adherence

What the study showed, in plain terms

The three multidrug regimens produced statistically similar eradication rates. Berberine was one component of antibiotic and acid-suppression treatment.

Key findings

  • Intention-to-treat eradication rates were 70%, 77% and 69%.

What this study can and cannot tell us

Open-label single-center study; no support for self-treating H. pylori with berberine alone.

Related papers in the corpus

Tier 2
Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori
Chen XX et al. · Journal of digestive diseases · 2022
Tier 2
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment
Zhang J et al. · Journal of digestive diseases · 2020
Tier 2
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial
Zhang D et al. · Medicine · 2017
Tier 2
Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae
Rabbani GH et al. · The Journal of infectious diseases · 1987
Tier 2
Clinical trial of berberine in acute watery diarrhoea
Khin-Maung-U et al. · British medical journal (Clinical research ed.) · 1985

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology